Business Context and Reporting Period
This Form 8-K is a current report filed by Tempest Therapeutics, Inc. on February 25, 2026. The filing discloses the release of interim clinical trial results and an updated corporate presentation regarding the Company's lead asset, TPST-2003.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical development milestones rather than financial performance data.
Material Changes and Events
- Clinical Trial Update: The Company announced interim results from the ongoing REDEEM-1 trial of TPST-2003.
- Strategic Outlook: Management indicated preparations for a potential U.S. registrational study in 2026.
- Disclosure: An updated corporate presentation was posted to the Company's investor relations website.
Guidance, Outlook, and Risks
Management commentary highlights the progression of TPST-2003 toward a potential U.S. registrational study in 2026. The filing does not contain specific financial guidance, risk factor updates, or details on contingencies beyond the standard clinical development timeline.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific interim data points from the REDEEM-1 trial.
- Examine the updated corporate presentation on the Company's website for detailed timelines regarding the 2026 registrational study.
- Verify the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K does not contain liquidity data.